Management of Recurrent Oral HSV‑1 After Incomplete Response to Standard Therapy

Treatment Duration and Continuation

• Continue oral acyclovir 800 mg twice daily until all lesions have completely healed, rather than stopping automatically at day 5. This extends the minimum 5‑day course to the point of clinical resolution. 1
• The 5‑day regimen is only a minimum; therapy must be prolonged until full healing is observed. 2

Assessment of Clinical Response

• If lesions show partial improvement at day 5, verify that the patient is truly immunocompetent and has adhered to the prescribed dose (800 mg BID). Then continue the same regimen until complete resolution. [2][3]
• If lesions do not improve or worsen after 5 days, consider a mis‑identified first episode, inadequate dosing, poor adherence, or possible acyclovir resistance. 4

Diagnostic Testing

• Do not rely on serologic HSV‑1 antibody testing for acute management because most adults are already seropositive and antibodies do not differentiate active from latent infection. 6

Management of Immunocompetent Patients

• Most recurrent episodes resolve within 5–7 days, but some require longer treatment; continue acyclovir until full healing. 2
• Re‑evaluate at day 7–10; if lesions persist, obtain viral culture with DST and consider that the episode may actually be a first outbreak requiring a 7–10 day minimum course. 2

Management of Immunocompromised Patients

• Increase oral dose to acyclovir 400 mg 3–5 times daily for more severe immunosuppression. 5
• Early IV therapy (acyclovir 5–10 mg/kg every 8 h) is recommended for extensive lesions, inability to take oral medication, or lack of response to oral therapy. [2][5]
• Obtain resistance testing at the first sign of treatment failure (no improvement after 7 days). Acyclovir resistance occurs in 10–30 % of immunocompromised patients, especially transplant recipients. 4
• Continue therapy until complete resolution; healing may take weeks in severely immunocompromised individuals. 5

Definition and Management of Acyclovir Resistance

• Resistance is defined as lack of clinical improvement after 7 days of appropriately dosed acyclovir plus laboratory evidence of reduced susceptibility (phenotypic DST or genotypic mutation). 4
• First‑line alternative: Foscarnet 40 mg/kg IV every 8 h (or 60 mg/kg IV every 12 h) for 10 days or until lesions heal. [5][4]
• Monitoring: Watch for nephrotoxicity and electrolyte disturbances during foscarnet therapy. 4
• Second‑line options (if foscarnet fails):
  
  • Cidofovir 5 mg/kg IV weekly (or topical 1–3 % gel).
  • Amenamevir (helicase‑primase inhibitor) for TK‑mutant resistant strains.
    (Both supported by clinical microbiology guidance.) 4
• Do not use valacyclovir or famciclovir for confirmed acyclovir‑resistant HSV, as cross‑resistance is common. [5][4]

Indications for Hospitalization and IV Acyclovir

• Severe oral disease preventing oral intake.
• Disseminated HSV infection (e.g., hepatitis, pneumonitis, encephalitis).
• Progressive disease in immunocompromised patients despite oral therapy.
• Suspected or confirmed acyclovir resistance requiring foscarnet.

Suppressive Therapy

• For patients with ≥ 6 recurrences per year, initiate daily suppressive acyclovir 400 mg twice daily after the current episode resolves. This reduces recurrence frequency by ≥ 75 %. [2][3]

Common Pitfalls to Avoid

• Stopping therapy at day 5 while lesions are still active leads to prolonged disease. 1
• Assuming every second episode is a true “recurrent” outbreak; some are actually the first clinical episode requiring a longer course. 2
• Delaying resistance testing in immunocompromised patients; obtain culture with DST promptly if lesions persist beyond 7 days. 4
• Using topical acyclovir alone; oral therapy is markedly more effective. [2][7]
• Failing to assess immune status (HIV, transplantation, chemotherapy, chronic steroids) before deciding on treatment intensity.

All facts are drawn from guideline‑level sources (MMWR Recommendations and Reports, Clinical Microbiology and Infection) and include the cited reference IDs for verification.